Market Cap 40.52M
Revenue (ttm) 0.00
Net Income (ttm) -7.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 43,608
Avg Vol 49,896
Day's Range N/A - N/A
Shares Out 8.87M
Stochastic %K 29%
Beta 0.27
Analysts Strong Sell
Price Target $11.33

Company Profile

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clin...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9349 4906
Address:
500 Collins Street, Level 15, Melbourne, Australia
Nuevoempresario
Nuevoempresario Aug. 19 at 3:15 PM
$ATHE something is cooking here 😝
0 · Reply
GA09
GA09 Aug. 18 at 5:37 PM
$ATHE Extremely quiet. I am sure working on multiple fronts in establishing a strategic relationship to start Phase 3 trial. We wake up one AM and ATHE is trading at $100/share (minimum)!!!!!
2 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:28 PM
$ATHE BUILD THE HYPE FOLKS…TELL THE WORLD!!!!!!!
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:28 PM
$ATHE LFG
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:28 PM
$ATHE 99 PROBLEMS BUT ATHE AINT ONE
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:28 PM
$ATHE ONLY WAY IS UP….
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:27 PM
$ATHE 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:27 PM
$ATHE ARE YALL IDIOTS???? Quit selling!!!!!!!!!
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:27 PM
$ATHE Get your act together…why would you sell pure gold at a shit price?
0 · Reply
ShowM3Th3Mon3y69
ShowM3Th3Mon3y69 Aug. 13 at 8:40 PM
$ATHE The fact we are red after finding out we are patent protected for two more decades because people want to sell below $5 and secure single digit returns is reassuring that I’m not as dumb as I sometimes think I may be. Cheers to those smart enough to pretend the sell button doesn’t exist. To those selling, you owe your children’s children’s children an apology for making them work. By the time we lose our patent exclusivity this will 10,000x. Don’t steal $1M from future you so today you can have $100. Remember the guy who bought a $41 Pizza with 10,000 Bitcoin? That was only 16 years ago. We have 19 years of exclusivity…… -Money Man Todd
1 · Reply
Latest News on ATHE
Alterity Therapeutics granted new patent for ATH434

2026-08-17T09:47:20.000Z - 2 days ago

Alterity Therapeutics granted new patent for ATH434


Alterity Therapeutics initiated with a Buy at Craig-Hallum

2026-08-11T11:25:52.000Z - 8 days ago

Alterity Therapeutics initiated with a Buy at Craig-Hallum


Alterity Therapeutics Earnings release: Q4 2026

Jul 29, 2026, 8:00 PM EDT - 20 days ago

Alterity Therapeutics Earnings release: Q4 2026


Alterity Therapeutics initiated with a Buy at JonesResearch

2026-06-29T20:30:18.000Z - 7 weeks ago

Alterity Therapeutics initiated with a Buy at JonesResearch


Alterity Therapeutics assumed with a Buy at Ladenburg

2026-06-16T11:57:21.000Z - 2 months ago

Alterity Therapeutics assumed with a Buy at Ladenburg


Alterity Therapeutics Slides: Corporate presentation

Jun 15, 2026, 6:00 PM EDT - 2 months ago

Alterity Therapeutics Slides: Corporate presentation


Alterity Therapeutics management to meet with BTIG

2026-06-03T17:30:12.000Z - 2 months ago

Alterity Therapeutics management to meet with BTIG

ATHE


Alterity Therapeutics Earnings release: Q3 2026

Apr 29, 2026, 6:00 PM EDT - 3 months ago

Alterity Therapeutics Earnings release: Q3 2026


Alterity Therapeutics Transcript: KOL event

Apr 28, 2026, 1:00 PM EDT - 4 months ago

Alterity Therapeutics Transcript: KOL event


Alterity Therapeutics Quarterly report: H1 2026

Feb 24, 2026, 6:00 PM EST - 6 months ago

Alterity Therapeutics Quarterly report: H1 2026


Alterity Therapeutics provides corporate update

2026-01-30T12:38:43.000Z - 7 months ago

Alterity Therapeutics provides corporate update

ATHE


Alterity Therapeutics highlights key 2026 objectives

2026-01-21T12:36:56.000Z - 7 months ago

Alterity Therapeutics highlights key 2026 objectives

ATHE


Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Fri, 31 Oct 2025 07:25:00 -0400 - 10 months ago

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report


Alterity Therapeutics Earnings release: Q1 2026

Oct 31, 2025, 7:00 AM EDT - 10 months ago

Alterity Therapeutics Earnings release: Q1 2026


Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Mon, 08 Sep 2025 07:35:00 -0400 - 1 year ago

Alterity Therapeutics Raises A$20.0 million in Strategic Placement


Alterity Therapeutics Transcript: Biotech Showcase

Sep 2, 2025, 10:30 PM EDT - 1 year ago

Alterity Therapeutics Transcript: Biotech Showcase


Alterity Therapeutics to Present at the Biotech Showcase

Tue, 02 Sep 2025 07:25:00 -0400 - 1 year ago

Alterity Therapeutics to Present at the Biotech Showcase


Alterity Therapeutics Annual report: H2 2025

Aug 29, 2025, 3:30 AM EDT - 1 year ago

Alterity Therapeutics Annual report: H2 2025


Alterity Therapeutics Slides: Corporate Presentation

Jul 30, 2025, 6:00 PM EDT - 1 year ago

Alterity Therapeutics Slides: Corporate Presentation


Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Wed, 30 Jul 2025 07:25:00 -0400 - 1 year ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report


Alterity Therapeutics Earnings release: Q4 2025

Jul 29, 2025, 6:00 PM EDT - 1 year ago

Alterity Therapeutics Earnings release: Q4 2025


Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 30, 2025, 7:35 AM EDT - 1 year ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report


Alterity Therapeutics Earnings release: Q3 2025

Apr 29, 2025, 6:00 PM EDT - 1 year ago

Alterity Therapeutics Earnings release: Q3 2025


Alterity Therapeutics Quarterly report: H1 2025

Feb 27, 2025, 6:00 PM EST - 1 year ago

Alterity Therapeutics Quarterly report: H1 2025


Alterity Therapeutics Raises A$40.0 million in Placement

Feb 10, 2025, 7:25 AM EST - 1 year ago

Alterity Therapeutics Raises A$40.0 million in Placement


Alterity Therapeutics Transcript: Study Result

Jan 29, 2025, 8:01 PM EST - 1 year ago

Alterity Therapeutics Transcript: Study Result


Alterity Therapeutics Slides: Study Result

Jan 29, 2025, 8:01 PM EST - 1 year ago

Alterity Therapeutics Slides: Study Result


Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 24, 2025, 7:35 AM EST - 1 year ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report


Alterity Therapeutics Slides: Corporate Presentation

Jan 4, 2025, 8:00 PM EST - 1 year ago

Alterity Therapeutics Slides: Corporate Presentation


Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report


Alterity Therapeutics Earnings release: Q1 2025

Oct 30, 2024, 9:00 PM EDT - 1 year ago

Alterity Therapeutics Earnings release: Q1 2025


Alterity Therapeutics Annual report: H2 2024

Sep 26, 2024, 3:30 AM EDT - 2 years ago

Alterity Therapeutics Annual report: H2 2024


Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 31, 2024, 7:35 AM EDT - 2 years ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report


Alterity Therapeutics Earnings release: Q4 2024

Jul 30, 2024, 8:00 PM EDT - 2 years ago

Alterity Therapeutics Earnings release: Q4 2024


Alterity Therapeutics Transcript: Study Update

Jul 24, 2024, 6:30 PM EDT - 2 years ago

Alterity Therapeutics Transcript: Study Update


Alterity Therapeutics to Present at MST Financial Webinar

Jul 24, 2024, 7:35 AM EDT - 2 years ago

Alterity Therapeutics to Present at MST Financial Webinar


Nuevoempresario
Nuevoempresario Aug. 19 at 3:15 PM
$ATHE something is cooking here 😝
0 · Reply
GA09
GA09 Aug. 18 at 5:37 PM
$ATHE Extremely quiet. I am sure working on multiple fronts in establishing a strategic relationship to start Phase 3 trial. We wake up one AM and ATHE is trading at $100/share (minimum)!!!!!
2 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:28 PM
$ATHE BUILD THE HYPE FOLKS…TELL THE WORLD!!!!!!!
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:28 PM
$ATHE LFG
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:28 PM
$ATHE 99 PROBLEMS BUT ATHE AINT ONE
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:28 PM
$ATHE ONLY WAY IS UP….
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:27 PM
$ATHE 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:27 PM
$ATHE ARE YALL IDIOTS???? Quit selling!!!!!!!!!
0 · Reply
stckmuncher
stckmuncher Aug. 15 at 12:27 PM
$ATHE Get your act together…why would you sell pure gold at a shit price?
0 · Reply
ShowM3Th3Mon3y69
ShowM3Th3Mon3y69 Aug. 13 at 8:40 PM
$ATHE The fact we are red after finding out we are patent protected for two more decades because people want to sell below $5 and secure single digit returns is reassuring that I’m not as dumb as I sometimes think I may be. Cheers to those smart enough to pretend the sell button doesn’t exist. To those selling, you owe your children’s children’s children an apology for making them work. By the time we lose our patent exclusivity this will 10,000x. Don’t steal $1M from future you so today you can have $100. Remember the guy who bought a $41 Pizza with 10,000 Bitcoin? That was only 16 years ago. We have 19 years of exclusivity…… -Money Man Todd
1 · Reply
Dingo2
Dingo2 Aug. 13 at 2:14 PM
$ATHE Thinly traded. Slow and steady up is fine but I'm not going to b*tch if this one gets picked up by the "pack" someday as the play of the day 😄
0 · Reply
prismmarketview
prismmarketview Aug. 12 at 6:08 PM
$ATHE’s new U.S. patent provides composition-of-matter protection for ATH434’s crystalline mesylate form through at least 2045. If approved, the company expects the patent to be listed in the FDA Orange Book, adding another layer of potential market protection. https://prismmarketview.com/alterity-secures-u-s-patent-protection-for-ath434-through-2045/
0 · Reply
BioTuesdays
BioTuesdays Aug. 12 at 2:49 PM
$ATHE has announced that the United States Patent and Trademark Office (USPTO) has granted a new composition of matter patent for the company’s lead clinical asset, ATH434, an oral agent designed to treat the underlying pathology of neurodegenerative diseases such as multiple system atrophy (MSA), Parkinson’s disease, and related disorders. https://biotuesdays.com/2026/08/12/uspto-grants-alterity-new-composition-of-matter-patent/
0 · Reply
LewisDaKat
LewisDaKat Aug. 12 at 2:00 PM
$ATHE Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434 https://marketwirenews.com/stock/athe/news/alterity-therapeutics-announces-granting-of-new-u-s--6509405807645645.html?utm_source=stocktwits
0 · Reply
STACKD0E
STACKD0E Aug. 12 at 1:50 PM
0 · Reply
delans9
delans9 Aug. 12 at 1:35 PM
$ATHE surely this has to receive some love soon…
0 · Reply
jmcekc
jmcekc Aug. 12 at 12:59 PM
$ATHE Let’s go! Hope everyone has been buying the dips. Ready to take off soon.
0 · Reply
carlsbmoney
carlsbmoney Aug. 12 at 12:38 PM
$ATHE patent!!
0 · Reply
GA09
GA09 Aug. 12 at 12:38 PM
$ATHE From the CEO's letter. Notice "supporting potential partnerships and other opportunities to advance development". This implies they are talking to pharma and investors and the added patent extension adds value and also strengthens their position and their valuation. I think it is only a matter of time (sooner rather than later) that ATHE announces a strategic partner.
0 · Reply
tommy_john
tommy_john Aug. 12 at 12:09 PM
$ATHE when they finally notice this it will be beautiful
1 · Reply
focafoca99
focafoca99 Aug. 12 at 11:28 AM
$ATHE obtained a new U.S. composition of matter patent for ATH434, extending protection to 2045 and boosting its Phase 3 prospects.
0 · Reply
STACKD0E
STACKD0E Aug. 12 at 11:12 AM
0 · Reply